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Germ cell tumour chemotherapy
A. Horwich
Testicular Tumour Unit*, Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 SPT, UK.
The chemotherapy of metastatic non-seminatous germ cell
tumours (NSGCT) has now come of age with the publi-
cation of sufficient mature data to predict in the individual
patient both treatment efficacy and risk of severe side-effects.
The Indiana University Group, who pioneered the intro-
duction of cisplatin in combination with vinblastine and
bleomycin (PVB regimen - Einhorn & Donohue, 1977) have
recently reported long-term results in 229 patients treated
between 1974 and 1980 (Roth et al., 1988) indicating the
rarity of any recurrence more than 3 years after chemo-
therapy. This is supported by a decade of Royal Marsden
Hospital results in 320 patients treated between 1976 and
1985 (Peckham et al., 1988) and by the report in this issue
from the Charing Cross Hospital on 206 patients treated
between 1977 and 1988 (Hitchins et al., 1989). From these
and many other reports it seems clear that a large pro-
portion of patients with small volume metastatic NSGCT are
likely to be cured with chemotherapy alone. It is important
to recognise this group and to minimise the trauma and
morbidity of their treatment. Patients with more advanced
presentations have gained from improvements in chemo-
therapy (Williams et al., 1987; Peckham et al., 1988) and
from a greater understanding of the role of surgery for
masses remaining after chemotherapy (Hendry et al., 1987;
Donohue et al., 1982), but there remains some 10-20% of
patients with metastatic NSGCT who still die of their
malignant disease and in this group the current challenge is
to increase the efficacy of chemotherapy. This field also has
broader relevance to other cancers, since the sensitivity of
germ cell tumours to combination chemotherapy makes them
an important testing ground of determinants of chemo-
therapy response such as dose, dose intensity and alternating
regimens.
There is broad agreement between major centres that the
factors determining prognosis in patients with metastatic
germ cell tumours are volume and extent of metastatic
disease, often described by the Royal Marsden Hospital
stages which are given by Hitchins et al. (1989) and also by
the serum concentration of tumour markers (alphafeto-
protein AFP, human chorionic gonadotrophin HCG, lactate
dehydrogenase LDH). The Medical Research Council
Testicular Tumour Working Party (MRCTTWP) analysed
prognostic factors in 458 patients treated with chemotherapy
between 1976 and 1982 (MRC, 1985). Disease extent and
serum marker concentrations were found to be equally
important prognostic variables. The subgroup of 180 patients
with both small volume disease (RMH stages IM, IIA, IIB,
IIIA, IIIB, IVALI, IVAL2, IVBLI, IVBL2) and low marker
concentrations (AFP <500kU -1 and HCG 1,000iU1-)
had a 3-year survival rate of 91% compared with an
intermediate group of 205 patients whose survival rate was
72% and a poor prognosis group of 73 patients (one high
marker plus stages IVL3, liver CNS or bone involvement)
where the survival rate was 47%. The overall 3-year survival
was 75%, but, 2-year survivals had risen during the period
of study from 68% in 1976-8 to 89% in 1981-2. In the latter
period the survival of patients in the three prognostic groups
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were 95%, 85% and 54% respectively and it can thus be
seen that improvements during this treatment era were
predominantly in the intermediate group, leading to the
present perception of two prognostic groups with the major-
ity of patients in a 'good risk' category and the rest being
'poor risk'. The improvement of prognosis was not explained
by changes in drug combinations or stage or marker distri-
bution and was ascribed to more appropriate use of chemo-
therapy and post-chemotherapy surgery (MRC, 1985;
Einhorn, 1986).
A number of groups have produced prognostic classi-
fications and in general these are based on the distribution
and volume of metastatic disease, e.g. The Indiana
University (Einhorn et al., 1985) and the MD Anderson
Hospital (Logothetis et al., 1986). The Sloan Kettering
(MSKCC) have derived a prognostic index which enables
calculation of the probability of complete remission based on
actual values of LDH, HCG and the number of metastatic
sites (Bosl et al., 1983). The EORTC similarly defined four
prognostic groups following a multivariate analysis of prog-
nostic factors, the risk groups being defined by trophoblastic
histology, concentration of AFP, and the size and number of
lung metastases (Stoter et al., 1987).
Prognostic factor analyses have allowed stratification of
patients either into a good prognosis subgroup, when the
future challenge would be to develop less toxic treatments,
or into a relatively poor prognosis subgroup where the aim
should be to increase the efficacy of chemotherapy. A
difficulty with current work in this field is the lack of general
agreement on definition of 'good risk' and 'poor risk'
patients. This causes problems in interpretation of single-arm
studies since a broader definition of poor risk will apparently
lead to improved treatment results in both good risk and
poor risk categories. Bajorin et al. (1988) have compared
four definitions of 'poor risk' applying published criteria to
118 patients whose chemotherapy response was already
known. There was marked discordance in allocation of
patients to the risk groups and thus on the same set of
overall results different centres would have reported median
survival in poor risk patients to be 11.5 months (MSKCC),
15 months (Indiana University), or 23.5 months (EORTC)
and 2-year survivals to be respectively 21%, 37% and 45%.
A further problem with basing stratification on retrospective
analyses is the improvement of treatment results in successive
patient cohorts (MRC, 1985; Einhorn, 1986). New important
prognostic factors may be identified with increasing know-
ledge of teratoma tumour biology such as identification of
different subtypes of teratoma stem cells (Pera et al., 1988),
characterisation of oncogene expression (Watson et al.,
1986), and measurements of tumour proliferation (Sledge et
al., 1988; Price et al., 1988).
Since the seminal report by Einhorn and colleagues of the
efficacy of the cisplatin, vinblastine, bleomycin combination
(PVB) (Einhorn & Donohue, 1977) a range of approaches to
increasing chemotherapy efficacy have been investigated.
Randomised studies have not demonstrated benefit from
additional adriamycin or from maintenance vinblastine
(Einhorn & Williams, 1980). There is good evidence, how-
ever, that the substitution of etoposide for vinblastine (BEP,
Peckham et al., 1983) is more effective than PVB in
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advanced disease. Pizzocaro et al. (1985) report prolonged
disease free survival in 82.5% of 40 patients with advanced
metastatic disease (nodes > 10cm, lung masses >5cm, extra
pulmonary spread, AFP >1,000ngml-1 or HCG
>50,000miUml-1) and in the prospective randomised com-
parison of PVB and BEP reported by Williams et al. (1987)
patients with advanced disease on the Indiana University
staging system faired better with BEP (survival probability at
2 years 76% versus 48% with PVB). Other approaches tested
in prospective randomised studies have been dose escalation,
especially of cisplatin and the use of alternating regimens.
Following demonstration in germ cell tumours of dose
response for cisplatin (Samson et al., 1984) and the mitiga-
tion of cisplatin renal toxicity by hydration with hypertonic
saline (Ozols et al., 1984), this drug was tested at
40mgm-2 x 5, double the usual dose. Severe toxicity has
been demonstrated (Dougaard & Rorth, 1986). At the NCI
'double dose' cisplatin was combined with etoposide, vin-
blastine and bleomycin (PVeBV) and the regimen has been
compared with PVB in a prospective randomised trial in
'poor risk' patients (Ozols et al., 1988). Only 52 patients
were randomised and median follow-up at the time of
reporting was 4 years. The complete remission rate was
higher with PVeBV (88% vs. 67%, P=0.14) and relapse was
less common (17% vs. 41%, P=0.2). The actuarial 5-year
survival was 78% for PVeBV versus 48% for PVB (P=0.06)
and also disease free survival was significantly higher.
Ninety-one per cent of patients treated with PVeBV had
nadir total white blood-counts <1,0001- 1 and 88% had
neutropenic sepsis. Furthermore ototoxicity was severe and
12 patients required hearing aids following treatment.
Unfortunately, since standard dose BEP has been shown to
be superior to PVB in advanced disease (vide supra) it is not
clear that the survival benefits in the NCI study derived
from the increased dose of cisplatin rather than from the
inclusion of etoposide as an additional drug in the high dose
arm.
In single-arm studies dose escalation is being investigated
in conjunction with autologous bone-marrow transplantation
(Nichols et al., 1988; Mulder et al., 1988; Ahlgren et al.,
1988). The dose escalation study from Indiana University
settled on doses for phase 2 evaluation in relapsed germ cell
tumour patients of etoposide 1,200mgm 2 combined with
carboplatin 1,500mgm-2, but, even with autologous bone-
marrow support bone marrow suppression was extremely
severe (Nichols et al., 1988) and of the first 33 patients
entered in the study there were seven treatment deaths
associated with granulocytopaenia and infection. Of seven
complete remissions four were clearly in patients refractory
to standard doses of cisplatin.
A different approach to intensification of treatment has
been to reduce the interval between courses of chemo-
therapy. In a rapidly proliferating tumour, growth between
cycles may be a cause of apparent resistance, and delay in
giving chemotherapy courses does appear to be an adverse
prognostic factor (Peckham et al., 1985; Crawford et al., this
issue). Wettlaufer et al. (1984) demonstrated tolerance of a 7-
day cycle of platinum, vincristine and bleomycin, the impor-
tant initiative being the use of vincristine rather than the
more myelosuppressive vinblastine or etoposide. A number
of single-arm studies have explored this method of intensi-
fying chemotherapy in high risk cases (Daniels et al., 1987;
Murray et al., 1987; Horwich et al., 1989). The Royal
Marsden study in 29 patients was based on the subgroup
identified in the MRC analysis (1985) to have a predicted
survival rate of 55%. Four courses of bleomycin, vincristine,
cisplatin (BOP) at 7-day intervals were followed by three
courses of BEP at 21-day intervals. Eighty-five per cent of 27
evaluable patients remained free from progressive disease at
a median follow-up of 2 years (Horwich et al., 1989).
Results of single-arm studies with alternating regimens
have been very impressive (Newlands et al., 1986; Logothetis
et al., 1985). However, these are complex regimens which
have not yet been tested by multi-centre groups in controlled
trials and it may be that their benefit derives from factors
other than drug alternation. The POMB/ACE regimen (cis-
platin, vincristine, methotrexate, bleomycin/actinomycin-D,
cyclophosphamide, etoposide), was developed in the Charing
Cross Hospital in 1977 and was reported to be effective in
adverse subgroups of patients, with complete remissions in
14 out of 16 patients with liver metastases and 6 out of 7
with brain metastases (Newlands et al., 1986). Volume of
metastatic disease did not appear to be adverse with this
schedule, however, survival in the 41 patients with serum
HCG >50,000iUl-1 or AFP>500kUl -1 was 64% com-
pared to 90% in 40 patients with lower marker concen-
trations. This regimen has been investigated independently
by Cullen et al. (1988) who also found it to be highly
effective in adverse subgroups. In their study of 60 patients
treated between 1979 and 1987 there were 4 early deaths, 5
failures of remission induction and 4 relapses from
remission. Four of 6 patients with liver metastases and 3 of 4
with brain metastases were free from progression at the time
of reporting. Nevertheless in this series patients identified as
poor risk on the MRC classification (MRC (1985), very
large volume plus high markers) had a 54% survival rate
and this is comparable with standard regimens. Logothetis et
al. (1985) report excellent results alternating CISCA2 (adria-
mycin, cyclophosphamide, cisplatin), with VBiv (vinblastine,
bleomycin) with complete remission in 44 of 48 patients,
though myelosuppressive complications were common with
infections occurring after 45% of chemotherapy courses. On
the other hand the MSKCC study of alternating EP/VAB-6
(Bosl et al., 1987) did not suggest that this approach was
superior to standard VAB-6 and the EORTC randomised
trial showed alternating BEP and PVB to be no better than
BEP (Stoter et al., 1986). At present treatment intensification
and alternation of drug regimens have not been proved to
improve survival in adverse presentations of germ cell
tumour, but, these approaches do appear promising and
merit evaluation in prospective randomised trials.
In patients with less extensive metastatic NSGCT the
prognosis on standard chemotherapy is excellent (MRC,
1985; Williams et al., 1987; Peckham et al., 1988) and
toxicity is an important issue in the choice of treatment. The
major life threatening complications of drug regimens
employed for germ cell tumours include myelosuppression
and bleomycin-induced pneumonitis. Some patients suffering
severe nausea and vomiting, abdominal cramps or dermatitis
find it difficult to continue with chemotherapy. Some side
effects are chronic and the full impact on the health of the
patient may not yet be manifest. These include renal damage
and ototoxicity due to cisplatin (Daugaard et al., 1988;
Hamilton et al., 1989) and Reynaud's phenomenon due to
bleomycin (Roth et al., 1988). Approaches to a reduction of
chemotherapy toxicity include reduction of drug dosage,
reduction of the number of drugs, the use of less toxic drugs
or drug analogues, and the reduction of the total number of
chemotherapy courses. A prospective randomised trial from
Indiana University compared PVB containing vinblastine at
0.4mgkg-1 with the dose of 0.3mgkg-1 and suggested that
therapeutic results were equivalent with considerably less
toxicity with the lower dose (Einhorn & Williams, 1980).
However, this study was very small with only 26 and 27
patients in each arm and failure analysis would suggest that
dosage of cisplatin (Samson et al., 1984) and of etoposide
(Brada et al., 1987) may be of critical importance for anti-
tumour effect. Total drug dosage can also be reduced by
avoiding maintenance chemotherapy (Einhorn et al., 1981)
or by reducing the total number of induction chemotherapy
courses. A preliminary analysis of 184 good prognosis
patients treated with either three or four courses of BEP
indicates no difference in efficacy (Einhorn et al., 1988).
A number of recent trials have suggested that bleomycin
may be an unnecessary component of the chemotherapy of
good prognosis patients. The EORTC study (Stoter et al.,
1987) contained 180 good risk patients with lymph node
metastases <5cm in diameter, lung metastases <2cm in158 A. HORWICH
diameter, AFP < 1,000 ngml -1 and HCG <10,000 ngml -1.
The study compared BEP with EP and CR rates were 95.5%
and 95.2% respectively. There was no difference in contin-
uous disease free survival (94% and 92%). Those treated
without bleomycin did not suffer lung toxicity or significant
skin toxicity and, rather more surprisingly, BEP was more
myelosuppressive than EP. A trial from the Australian Germ
Cell Neoplasm Trial Group has compared PVB with PV in
104 patients with a 'good prognosis' metastatic testicular
cancer (Levi et al., 1986). No significant difference in
response was found. The MSKCC compared VAB-6 alter-
nating with EP to a non-randomised control group treated
with VAB-6 alone and found no advantage with the alter-
nating schedule (Bosl et al., 1988).
Much of the toxicity of cisplatin can be avoided by use of
the recently developed analogue carboplatin (Calvert et al.,
1985). At conventional dosage carboplatin does not cause
significant renal toxicity, neuro-toxicity or oto-toxicity and
gastro-intestinal side effects are less severe. The drug is
predominantly excreted by the kidneys and myelosuppression
is related to glomerular filtration rate as well as dose
(Calvert et al., 1985). There is some evidence that appropri-
ate dose adjustment of carboplatin is also required for
optimum anti-tumour effect. The Royal Marsden Hospital
Testicular Tumour Unit has performed a pilot study of the
combination of carboplatin, etoposide and bleomycin (CEB)
in metastatic non-seminomatous germ cell tumours. An
analysis of the first 47 patients in this study revealed
treatment failure in five patients (three with residual malig-
nancy at surgery, and two recurrences). Carboplatin dose
was based on a calculation of the dose required to achieve a
particular serum concentration x time (AUC) (Calvert et al.,
1985). Since a range of doses of carboplatin was employed in
this study a suggestion emerged that inadequate carboplatin
dosage predisposed to recurrence since the AUCs in the five
unsuccessful treatments were 2.6, 3.4, 3.5, 3.8 and
3.9mgml-1 x min compared with a median of
5mgml -1 x min in patients successfully treated. The five
patients with active tumour after CEB have all been success-
fully re-treated with further chemotherapy and all patients in
this study are currently disease free. A current MRC
prospective randomised trial is comparing BEP and CEB
chemotherapy in good prognosis patients.
Considerable progress has been made in identifying
chemotherapeutic strategies, of reduced toxicity. However, it
is important to ensure that there is not an associated
compromise of anti-tumour efficacy. Even in good prognosis
subgroups the risk to the patient of dying from progressive
malignant disease is far higher than the risk of dying from
treatment toxicity.
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